In the evolving landscape of oncology, where innovation and research intertwine, Kura Oncology, Inc. (Nasda...

Published | Modified September 30, 2024
CSIMarket Newsroom | CSIMarket.com

Unlocking Hope: Kura Oncology’s Ziftomenib Phase 1 Breakthrough in Treating Acute Myeloid Leukemia Published in The Lancet Oncology’

In the evolving landscape of oncology, where innovation and research intertwine, Kura Oncology, Inc. (Nasdaq: KURA) has taken a significant stride forward. On September 30, 2024, the company proudly announced the publication of its KOMET-001 Phase 1 study manuscript in the reputable journal, ’The Lancet Oncology’. The paper

Sources for this article: Based on Kura Oncology Inc ’s official statement and CSIMarket.com Customer Analytics Research for Kura Oncology Inc

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License